Table 3.
Weighted Prevalence Estimates of the Most Commonly Used Prescription and Over-the-counter (OTC) Medications by Age and Gendera
| Medication | Estimated Prevalence, % (95% CI) | ||||||
|---|---|---|---|---|---|---|---|
| Aged 57–64 y (n = 1016) |
Aged 65–74 y (n = 1082) |
Aged 75–85 y (n = 878) |
Total (N = 2976) |
||||
| Men (n = 525) |
Women (n = 491) |
Men (n = 543) |
Women (n = 539) |
Men (n = 377) |
Women (n = 501) |
||
| Aspirin (OTC available) | 23.8 (19.4–28.3) | 20.5 (15.5–25.5) | 34.5 (29.9–39.1) | 26.6 (23.0–30.1) | 39.1 (32.1–46.1) | 31.2 (26.0–36.5) | 28.0 (25.3–30.7) |
| Weighted No. | 151 | 124 | 175 | 142 | 121 | 123 | 835 |
| Hydrochlorothiazide | 9.1 (6.1–12.2) | 16.6 (11.8–21.4) | 15.2 (10.9–19.5) | 16.9 (13.0–20.7) | 19.4 (15.1–23.7) | 20.0 (15.2–24.8) | 15.6 (13.4–17.7) |
| Weighted No. | 58 | 100 | 77 | 90 | 60 | 79 | 464 |
| Atorvastatin | 15.8 (11.7–19.8) | 9.6 (6.8–12.3) | 15.5 (11.9–19.0) | 13.4 (10.1–16.7) | 15.6 (11.8–19.4) | 11.5 (7.6–15.3) | 13.4 (11.9–15.0) |
| Weighted No. | 100 | 58 | 78 | 71 | 48 | 45 | 401 |
| Levothyroxine | 3.1 (1.8–4.5) | 16.4 (11.7–21.1) | 7.6 (5.2–10.0) | 18.8 (15.7–21.9) | 9.6 (5.8–13.3) | 20.9 (17.2–24.6) | 12.4 (10.8–14.0) |
| Weighted No. | 20 | 99 | 38 | 100 | 30 | 82 | 369 |
| Lisinopril | 9.9 (6.8–13.0) | 9.6 (5.4–13.8) | 14.8 (11.5–18.2) | 10.0 (7.2–12.8) | 21.1 (17.5–24.7) | 12.8 (9.5–16.1) | 12.2 (10.5–14.0) |
| Weighted No. | 63 | 58 | 75 | 53 | 65 | 51 | 365 |
| Metoprolol | 9.6 (7.6–11.7) | 8.0 (5.0–11.1) | 12.1 (8.5–15.6) | 9.4 (7.0–11.7) | 15.2 (10.9–19.6) | 14.4 (11.7–17.2) | 10.9 (9.6–12.2) |
| Weighted No. | 61 | 49 | 61 | 50 | 47 | 57 | 324 |
| Simvastatin | 9.3 (7.0–11.7) | 5.3 (3.0–7.7) | 11.6 (8.7–14.5) | 8.7 (6.0–11.4) | 18.0 (13.2–22.8) | 8.6 (5.3–11.8) | 9.6 (8.5–10.7) |
| Weighted No. | 59 | 32 | 59 | 46 | 56 | 34 | 286 |
| Atenolol | 6.2 (3.7–8.8) | 6.9 (4.5–9.3) | 9.5 (7.1–11.8) | 8.4 (5.3–11.5) | 13.3 (8.8–17.8) | 11.0 (8.3–13.8) | 8.7 (7.5–9.9) |
| Weighted No. | 39 | 42 | 48 | 44 | 41 | 44 | 258 |
| Amlodipine | 6.8 (3.6–9.9) | 7.9 (5.2–10.7) | 11.1 (8.2–14.0) | 7.5 (5.1–9.8) | 8.1 (4.7–11.4) | 9.3 (6.5–12.1) | 8.3 (7.5–9.2) |
| Weighted No. | 43 | 48 | 56 | 40 | 25 | 37 | 249 |
| Metformin | 9.7 (6.3–13.1) | 8.4 (5.6–11.2) | 8.7 (6.2–11.3) | 8.5 (6.4–10.6) | 6.0 (3.3–8.6) | 6.0 (3.9–8.2) | 8.2 (7.0–9.4) |
| Weighted No. | 61 | 51 | 44 | 45 | 18 | 24 | 244 |
| Acetaminophen (OTC available) | 3.5 (1.6–5.5) | 9.4 (5.5–13.3) | 6.7 (4.2–9.2) | 9.5 (6.7–12.2) | 5.8 (3.2–8.4) | 10.3 (7.8–12.8) | 7.5 (6.0–9.0) |
| Weighted No. | 22 | 57 | 34 | 50 | 18 | 41 | 222 |
| Furosemide | 2.3 (1.1–3.5) | 5.6 (2.7–8.5) | 8.7 (6.1–11.3) | 5.6 (3.7–7.5) | 8.4 (5.3–11.5) | 10.5 (7.7–13.2) | 6.4 (5.3–7.5) |
| Weighted No. | 15 | 34 | 44 | 30 | 26 | 41 | 190 |
| Ezetimibe | 4.8 (2.7–7.0) | 3.6 (1.8–5.4) | 6.9 (4.6–9.2) | 5.4 (3.1–7.7) | 5.1 (1.8–8.3) | 5.9 (2.8–9.1) | 5.2 (4.2–6.2) |
| Weighted No. | 31 | 22 | 35 | 29 | 16 | 23 | 155 |
| Valsartan | 2.7 (1.0–4.4) | 5.3 (2.8–7.8) | 3.7 (2.0–5.5) | 7.0 (4.7–9.2) | 3.4 (0.9–6.0) | 5.4 (3.6–7.2) | 4.6 (3.8–5.4) |
| Weighted No. | 17 | 32 | 19 | 37 | 11 | 21 | 137 |
| Alendronate | 0.3 (0–0.8) | 5.4 (3.1–7.8) | 1.2 (0.5–1.8) | 9.3 (6.0–12.5) | 1.8 (0.1–3.5) | 9.4 (6.7–12.1) | 4.5 (3.6–5.4) |
| Weighted No. | 2 | 33 | 6 | 49 | 6 | 37 | 133 |
| Warfarin | 2.5 (1.2–3.9) | 1.7 (0.7–2.7) | 4.4 (2.8–6.1) | 2.7 (1.4–3.9) | 12.7 (8.5–16.9) | 7.3 (4.8–9.9) | 4.4 (3.7–5.1) |
| Weighted No. | 16 | 10 | 22 | 14 | 39 | 29 | 131 |
| Omeprazole (OTC available) | 2.9 (1.4–4.5) | 4.2 (1.5–6.9) | 5.4 (3.1–7.6) | 3.8 (1.9–5.7) | 7.1 (3.8–10.3) | 4.4 (2.0–6.8) | 4.4 (3.4–5.4) |
| Weighted No. | 19 | 25 | 27 | 20 | 22 | 17 | 130 |
| Clopidogrel | 3.4 (1.7–5.1) | 3.9 (0.8–6.9) | 6.1 (3.8–8.5) | 3.3 (1.5–5.1) | 5.3 (3.1–7.5) | 4.8 (2.6–6.9) | 4.3 (3.3–5.3) |
| Weighted No. | 22 | 23 | 31 | 18 | 16 | 19 | 129 |
| Albuterol | 2.3 (0.6–4.0) | 5.9 (3.3–8.4) | 6.1 (3.7–8.6) | 4.3 (1.9–6.7) | 3.9 (1.5–6.3) | 3.3 (2.0–4.7) | 4.3 (3.3–5.3) |
| Weighted No. | 14 | 35 | 31 | 23 | 12 | 13 | 129 |
| Conjugated estrogens | NA | 9.1 (6.1–12.2) | NA | 9.2 (5.6–12.8) | NA | 5.1 (2.9–7.4) | 4.2 (3.1–5.2) |
| Weighted No. | NA | 55 | NA | 49 | NA | 20 | 124 |
Abbreviations: CI, confidence interval; NA, not applicable.
a
Estimates (numbers and percentages) weighted to account for differential probabilities of selection and differential nonresponse; CIs based on inversion of Wald tests constructed with the use of design-based SEs. Medications used by respondent as a single or multicomponent product. Prescription-only and OTC medications were combined, because prescription status varies for several medications depending on formulation and strength and because medication data collection was limited to drug names.